CN115487303A - 一种抗炎抗菌植物多酚凝胶及其制备方法 - Google Patents
一种抗炎抗菌植物多酚凝胶及其制备方法 Download PDFInfo
- Publication number
- CN115487303A CN115487303A CN202110669784.7A CN202110669784A CN115487303A CN 115487303 A CN115487303 A CN 115487303A CN 202110669784 A CN202110669784 A CN 202110669784A CN 115487303 A CN115487303 A CN 115487303A
- Authority
- CN
- China
- Prior art keywords
- plant polyphenol
- gel
- inflammatory
- solution
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 36
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 36
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 27
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000001879 gelation Methods 0.000 title description 2
- 241000196324 Embryophyta Species 0.000 claims abstract description 35
- 108010020346 Polyglutamic Acid Proteins 0.000 claims abstract description 13
- 229920002643 polyglutamic acid Polymers 0.000 claims abstract description 13
- 229940069521 aloe extract Drugs 0.000 claims abstract description 12
- 229920001661 Chitosan Polymers 0.000 claims abstract description 7
- 229930003935 flavonoid Natural products 0.000 claims abstract description 4
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 4
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 4
- 239000000499 gel Substances 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 10
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 241001116389 Aloe Species 0.000 claims description 7
- 235000011399 aloe vera Nutrition 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 5
- 125000005456 glyceride group Chemical group 0.000 claims description 5
- -1 carbondiamine Chemical compound 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 150000001718 carbodiimides Chemical class 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 238000004537 pulping Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 235000014104 aloe vera supplement Nutrition 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 abstract description 8
- 108090000695 Cytokines Proteins 0.000 abstract description 8
- 230000000770 proinflammatory effect Effects 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 4
- 206010065687 Bone loss Diseases 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- 208000028169 periodontal disease Diseases 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 201000001245 periodontitis Diseases 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000002768 Kirby-Bauer method Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000001143 Periodontal Abscess Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010044016 Tooth abscess Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及凝胶材料领域,具体涉及一种抗炎抗菌植物多酚凝胶及其制备方法。该多酚凝胶是通过壳聚糖、聚谷氨酸、芦荟提取液和植物多酚制备而成;所述的植物多酚为类黄酮。本发明制备得到的植物多酚@γ‑PGA‑CO凝胶,一方面解决了口腔护理产品抑菌、消炎效果不够理想的固有问题,使得产品具有更高的渗透性,更容易被人体吸收,提高了抗菌、消炎的效果;另一方面,会减少促炎细胞因子的分泌,同时会增加抗炎细胞因子的数量。通过引起与口腔细胞的更高附着水平以及更低的炎症和骨质流失而显示出其抗菌作用。
Description
技术领域
本发明涉及凝胶材料领域,具体涉及一种抗炎抗菌植物多酚凝胶及其制备方法。
背景技术
口腔、咽喉是进食和呼吸的通道,又是饮食水进入人体的必经之路,与人的健康生存息息相关。口腔问题主要是由细菌引起的,包括牙周炎、牙周脓肿、牙龈出血、口腔炎症及口臭等。有关调查结果表明,近年来95%以上的成年人正在遭受不同程度的口腔问题困扰。
然而,已有的口腔护理类漱口液为了迎合消费者,改善产品的口味,往往会降低有效成分的含量,使其预防龃齿的效果不够理想;此外,为了追求产品的功能性作用,比如抗菌、消炎,通常会采取提高杀菌剂用量的做法,但这样会增加产品对口腔黏膜的刺激性,也难以满足消费者的需求。
而多酚在治疗和预防牙周疾病方面作为抗菌和消炎物质具有巨大潜力。多酚会减少促炎细胞因子的分泌,同时会增加抗炎细胞因子的数量。类黄酮是一类同时用作抗氧化剂和消炎剂的多酚,植物多酚对口腔病原体具有很大的抗菌和消炎作用。但是刺激性较强,如何降低刺激性的同时又能增加抗炎抗菌效果成为了亟待解决的技术问题。
发明内容
本发明要解决的技术问题是提供一种抗炎抗菌植物多酚凝胶,其能有效促进口腔伤口愈合,且具有较强的抑菌、消炎、抗过敏性能,对牙周炎也具有较好的预防和治疗功效。
本发明还提供了一种抗炎抗菌植物多酚凝胶的制备方法。
本发明为了实现上述目的所采用的技术方案为:
本发明提供了一种抗炎抗菌植物多酚凝胶,其特征在于,所述多酚凝胶是通过壳聚糖、聚谷氨酸、芦荟提取液和植物多酚制备而成;所述的植物多酚为类黄酮。
本发明还提供了一种抗炎抗菌植物多酚凝胶的制备方法,包括以下步骤:
(1)将聚谷氨酸首先加入到芦荟提取液中,搅拌20-30min后,加入壳聚糖、蒸馏水,搅拌溶解形成均一的水溶液,然后加入碳化二胺和N-羟基琥珀酰亚胺,反应形成γ-PGA-CO溶液;
(2)将植物多酚添加到γ-PGA-CO溶液中,反应形成水凝胶,将凝胶在去离子水中透析纯化,并溶胀平衡,干燥,得到植物多酚@γ-PGA-CO凝胶。
进一步的,步骤(1)中,所述聚谷氨酸∶芦荟提取液:壳寡糖∶碳化二胺∶N-羟基琥珀酰亚胺:水的投料质量比为1~3:0.1:2~6:5:4:0.15。
本发明所使用的芦荟提取液通过以下方法制备而成:将新鲜的芦荟去皮后,浸入50%乙醇溶液中,20min后取出,然后进行打浆,加入由柠檬酸脂肪酸甘油酯、10%乙醇水溶液组成的提取液,搅拌2-2.5h,然后进行挤压过滤即可。
上述芦荟和提取液的料液比为1g:8mL;所述柠檬酸脂肪酸甘油酯、10%乙醇水溶液的质量比为1:9。
进一步的,步骤(1)中,所述反应为4℃下冰浴10-15min;步骤(2)中,所述反应为在室温下反应2-4h。
进一步的,步骤(2)中,所述γ-PGA-CO溶液和植物多酚的质量比为3~8:3~7。
本发明所使用的碳化二胺优选1-(3-二甲基氨基丙基)-3-乙基碳二亚胺,简称EDC;N-羟基琥珀酰亚胺简称NHS。
本发明在植物多酚的基础上聚合γ-PGA-CO,能增加其抗菌性能及生物相容性,在预防和治疗牙周疾病的同时减少对口腔粘膜的刺激性。
本发明的有益效果为:
(1)本发明制备得到的植物多酚@γ-PGA-CO凝胶,一方面解决了口腔护理产品抑菌、消炎效果不够理想的固有问题,使得产品具有更高的渗透性,更容易被人体吸收,提高了抗菌、消炎的效果;另一方面,会减少促炎细胞因子的分泌,同时会增加抗炎细胞因子的数量。通过引起与口腔细胞的更高附着水平以及更低的炎症和骨质流失而显示出其抗菌作用。
(2)本发明制备的凝胶体系在治疗和预防牙周疾病方面作为抗菌和消炎物质具有巨大潜力,会减少促炎细胞因子的分泌,同时会增加抗炎细胞因子的数量,对口腔病原体具有很大的抗菌和消炎作用,这对预防和治疗牙周疾病很重要。
具体实施方式
下面将结合具体实施例来详细说明本发明,在此本发明的示意性实施例及其说明用来解释本发明,但并不作为对本发明的限定。
实施例1
一种抗炎抗菌植物多酚凝胶,包括3份γ-PGA-CO和7份植物多酚,制备植物多酚@γ-PGA-CO凝胶。
制备方法如下:
(1)将1份聚谷氨酸首先加入到0.1份芦荟提取液中,搅拌20-30min后,加入2份壳聚糖、0.15份蒸馏水,搅拌溶解形成均一的水溶液,然后加入5份碳化二胺和4份N-羟基琥珀酰亚胺,4℃下冰浴10-15min形成γ-PGA-CO溶液;
(2)将7份植物多酚添加到3份γ-PGA-CO溶液中,室温下反应2-4h形成水凝胶,将凝胶在去离子水中透析纯化,并溶胀平衡,干燥,得到植物多酚@γ-PGA-CO凝胶。
3、根据权利要求2所述的制备方法,其特征在于,步骤(1)中,所述聚谷氨酸∶壳寡糖∶碳化二胺∶N-羟基琥珀酰亚胺:水的投料质量比为1~3:0.1:2~6:5:4:0.15。
芦荟提取液通过以下方法制备而成:将新鲜的芦荟去皮后,浸入50%乙醇溶液中,没过芦荟即可,20min后取出,然后进行打浆,每1g芦荟中加入8mL由柠檬酸脂肪酸甘油酯、10%乙醇水溶液组成的提取液,搅拌2.5h,然后进行挤压过滤即可。
实施例2
一种抗炎抗菌植物多酚凝胶,以聚谷氨酸为投料比例基准,聚谷氨酸∶芦荟提取液:壳寡糖∶碳化二胺∶N-羟基琥珀酰亚胺:水的投料质量比例范围为2:0.1:4:5:4:0.15;4℃冰浴13min,获得γ-PGA-CO溶液。
其他制备方法同实施例1。
实施例3
一种抗炎抗菌植物多酚凝胶,以聚谷氨酸为投料比例基准,聚谷氨酸∶芦荟提取液:壳寡糖∶碳化二胺∶N-羟基琥珀酰亚胺:水的投料质量比例范围为3:0.1:6:5:4:0.25;4℃冰浴10min,获得γ-PGA-CO溶液。
其他制备方法同实施例1 。
对比例1
原料中不包括壳聚糖,其他原料以及制备方法与实施例1一样。
对比例2
原料中不包括植物多酚,其他原料以及制备方法与实施例1一样。
对比例3
原料中不包括芦荟提取液,其他原料以及制备方法与实施例1一样。
效果实施例
(一)抑菌性能测试
测试各凝胶分别对金黄色葡萄球菌、白色念球菌、大肠杆菌的抑菌率,采用圆盘琼脂扩散试验(Disc agar diffusion test),根据圆盘周围出现生长抑制圈大小判定抑菌效果,抑菌率越高表明抑菌性能越好,测试结果如表1所示:
表1
由表1可看出,本发明实施例对三个菌种的抑菌率均明显高于对比例,表明本发明具有较强的抑菌性能,其中实施例1的抑菌性能最好。对比例1、2、3的抑菌率均有大幅度下降,说明壳寡糖、植物多酚、芦荟提取液均能有效提高凝胶的抑菌性能。
(二)牙周病疗效测试
1、建立小鼠牙周炎动物模型:将体重为230-250g之间的成年大鼠,实验前4d,按照20mg/只的剂量经大鼠肌肉注射卡那霉素,1次/d,然后给予抗生素3d后,取50g/L的低粘性碳氧甲基纤维素牙龈卟啉菌381悬液,经管饲使细菌涂于龈缘至整个口腔,1次/d,共涂3d;6周后,模型大鼠牙槽骨明显丧失,诱导牙周炎大鼠模型成功。
2、将建立的大鼠模型进行分组,每组5只,然后进行喷施实施例1及对比例3和4制备的凝胶,使用方法::每天早晚各一次使用,3周后复查口腔情况,计算出牙周病治疗有效率,牙周病治疗有效率=牙周病治疗有效的小鼠数量/总数量×100%,测试结果如表2所示。
表2
由表2可以看出,本发明实施例1的牙周病治疗有效率均明显高于对比例,表明本发明的牙周病疗效较好。
Claims (7)
1.一种抗炎抗菌植物多酚凝胶,其特征在于,所述多酚凝胶是通过壳聚糖、聚谷氨酸、芦荟提取液和植物多酚制备而成;所述的植物多酚为类黄酮。
2.一种如权利要求1所述的抗炎抗菌植物多酚凝胶的制备方法,其特征在于,包括以下步骤:
(1)将聚谷氨酸首先加入到芦荟提取液中,搅拌20-30min后,加入壳聚糖、蒸馏水,搅拌溶解形成均一的水溶液,然后加入碳化二胺和N-羟基琥珀酰亚胺,反应形成γ-PGA-CO溶液;
(2)将植物多酚添加到γ-PGA-CO溶液中,反应形成水凝胶,将凝胶在去离子水中透析纯化,并溶胀平衡,干燥,得到植物多酚@γ-PGA-CO凝胶。
3.根据权利要求2所述的制备方法,其特征在于,步骤(1)中,所述聚谷氨酸∶芦荟提取液:壳寡糖∶碳化二胺∶N-羟基琥珀酰亚胺:水的投料质量比为1~3:0.1:2~6:5:4:0.15。
4.根据权利要求2或3所述的制备方法,其特征在于,步骤(1)中,所述芦荟提取液通过以下方法制备而成:将新鲜的芦荟去皮后,浸入50%乙醇溶液中,20min后取出,然后进行打浆,加入由柠檬酸脂肪酸甘油酯、10%乙醇水溶液组成的提取液,搅拌2-2.5h,然后进行挤压过滤即可。
5.根据权利要求4所述的制备方法,其特征在于,所述芦荟和提取液的料液比为1g:8mL;所述柠檬酸脂肪酸甘油酯、10%乙醇水溶液的质量比为1:9。
6.根据权利要求2所述的制备方法,其特征在于,步骤(1)中,所述反应为4℃下冰浴10-15min;步骤(2)中,所述反应为在室温下反应2-4h。
7.根据权利要求2或3所述的制备方法,其特征在于,步骤(2)中,所述γ-PGA-CO溶液和植物多酚的质量比为3~8:3~7。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110669784.7A CN115487303A (zh) | 2021-06-17 | 2021-06-17 | 一种抗炎抗菌植物多酚凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110669784.7A CN115487303A (zh) | 2021-06-17 | 2021-06-17 | 一种抗炎抗菌植物多酚凝胶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115487303A true CN115487303A (zh) | 2022-12-20 |
Family
ID=84463973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110669784.7A Pending CN115487303A (zh) | 2021-06-17 | 2021-06-17 | 一种抗炎抗菌植物多酚凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115487303A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102321256A (zh) * | 2011-09-06 | 2012-01-18 | 南开大学 | 生物相容性γ-聚谷氨酸水凝胶制备方法 |
TW201722395A (zh) * | 2015-12-21 | 2017-07-01 | Homeway Technology Co Ltd | 遠紅外線潔牙凝膠 |
RU2732241C1 (ru) * | 2020-05-06 | 2020-09-14 | Общество с ограниченной ответственностью "ГельПласт" | Биодеградируемая лечебно-профилактическая гидрогелевая пластина и способ её получения (варианты) |
CN112402688A (zh) * | 2020-12-18 | 2021-02-26 | 曲阜师范大学 | 一种生物相容性且抗菌的快速止血纳米材料及其制备方法 |
CN112516053A (zh) * | 2020-12-30 | 2021-03-19 | 山东爱维德生物科技有限公司 | 一种用于婴儿湿疹的木立芦荟抑菌凝胶 |
-
2021
- 2021-06-17 CN CN202110669784.7A patent/CN115487303A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102321256A (zh) * | 2011-09-06 | 2012-01-18 | 南开大学 | 生物相容性γ-聚谷氨酸水凝胶制备方法 |
TW201722395A (zh) * | 2015-12-21 | 2017-07-01 | Homeway Technology Co Ltd | 遠紅外線潔牙凝膠 |
RU2732241C1 (ru) * | 2020-05-06 | 2020-09-14 | Общество с ограниченной ответственностью "ГельПласт" | Биодеградируемая лечебно-профилактическая гидрогелевая пластина и способ её получения (варианты) |
CN112402688A (zh) * | 2020-12-18 | 2021-02-26 | 曲阜师范大学 | 一种生物相容性且抗菌的快速止血纳米材料及其制备方法 |
CN112516053A (zh) * | 2020-12-30 | 2021-03-19 | 山东爱维德生物科技有限公司 | 一种用于婴儿湿疹的木立芦荟抑菌凝胶 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102085370B (zh) | 一种口腔炎症性疾病的口腔喷剂及其制备方法 | |
WO2015034252A1 (ko) | 한방추출물과 프로폴리스가 첨가된 치약 | |
CN105310960B (zh) | 一种新型多糖抗菌漱口液及其制备方法 | |
CN109481527B (zh) | 一种制备预防或治疗口腔疾病的中药组合物及其应用 | |
CN110946804B (zh) | 一种预防龋齿和口腔溃疡的漱口水及其制备方法 | |
CN108635378B (zh) | 一种用于日常口腔健康维护的口腔喷剂及其制备方法 | |
CN108815232A (zh) | 一种草本抗菌液 | |
CN112263606A (zh) | 一种中药含漱液及其制备方法 | |
US11806376B2 (en) | Pharmaceutical composition for treating oral ulcer and preparation method and application thereof | |
JP3035834B2 (ja) | プロポリス成分含有固状物とその製造方法並びに用途 | |
CN102406559A (zh) | 一种具有消炎止血功能的口腔清新喷雾剂及其制备方法 | |
KR20150061762A (ko) | 항우식 효능을 갖는 구강용 조성물 | |
CN115487303A (zh) | 一种抗炎抗菌植物多酚凝胶及其制备方法 | |
CN116236439A (zh) | 一种胶态银抑菌凝胶及其制备方法和应用 | |
CN110151915A (zh) | 一种蜂胶口腔护理液及其制备方法 | |
CN114053331B (zh) | 一种口腔抑菌组合物、口腔抑菌液、应用及制备方法 | |
CN111544361B (zh) | 一种抑制牙斑菌菌膜活性的漱口水 | |
CN110638910B (zh) | 一种具有抗病毒抑菌消炎作用的口气清新剂及其制备方法 | |
CN104906132B (zh) | 一种防治羔羊口炎的膏药制剂 | |
CN107998401A (zh) | 一种具有缓释效果的口腔药物制剂及其制备方法 | |
CN107898705B (zh) | 一种可预防龋齿和口腔溃疡的漱口水及其制备方法 | |
KR102141623B1 (ko) | 계피 추출물을 유효성분으로 포함하는 염증성 통증 예방 또는 치료용 조성물 | |
CN108066278B (zh) | 一种含有壳寡糖的妇科用凝胶及其制备方法 | |
CN102440912A (zh) | 一种具有消炎止血功能的口腔清洁泡腾片及其制备方法 | |
CN110051723A (zh) | 一种沙棘果口腔喷雾及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |